SCHEMBL4131466

SCHEMBL4131466

Cc1ccc(N=C2NC(=O)C(CNC(=O)Nc3cccc(C(F)(F)F)c3)S2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.50
MAPT P10636 3/20 0.46
TP53 P04637 2/20 0.46
KDR P35968 2/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
GRIK1 P39086 1/20 0.45
LMNA P02545 4/20 0.44
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
POLB P06746 1/20 0.43
XBP1 P17861 1/20 0.43
ALOX12 P18054 1/20 0.43
UBE2M P61081 1/20 0.43
DCUN1D1 Q96GG9 1/20 0.43
IDO1 P14902 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 1/20 0.42
RAF1 P04049 1/20 0.42
ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4131462 1.00 GAA (0.50) GAAMAPTTP53KDRMEN1
SCHEMBL4141017 0.87 GAA (0.48) GAAMAPTTP53MEN1KMT2A
SCHEMBL4141021 0.87 GAA (0.48) GAAMAPTTP53MEN1KMT2A
SCHEMBL4136415 0.85 GAA (0.47) GAAMAPTTP53MEN1KMT2A
SCHEMBL4136420 0.85 GAA (0.47) GAAMAPTTP53MEN1KMT2A
SCHEMBL4130910 0.85 GAA (0.49) GAAMAPTTP53KDRMEN1
SCHEMBL4130906 0.85 GAA (0.49) GAAMAPTTP53KDRMEN1
SCHEMBL4136991 0.84 GAA (0.48) GAAMAPTTP53MEN1KMT2A
SCHEMBL4136993 0.84 GAA (0.48) GAAMAPTTP53MEN1KMT2A
SCHEMBL4148492 0.83 GAA (0.45) GAAMAPTTP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156644-A1 Use of thiazole derivatives and analogues in the treatment of cancer BETAGENON AB (SE) 2009-06-18 US disclosed
US-20090136472-A1 Use of thiazole derivatives and analogues in disorders caused by free fatty acids BETAGENON AB (SE) 2009-05-28 US disclosed
WO-2008090327-A1 NEW COMBINATION FOR USE IN THE TREATMENT OF CANCER BETAGENON AB (SE) 2008-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156644-A1 Use of thiazole derivatives and analogues in the treatment of cancer TBXA2R, TSHR, FOLR1 GAA 2671/4885MAPT 3828/4885TP53 44/4885
US-20090136472-A1 Use of thiazole derivatives and analogues in disorders caused by free fatty acids FFAR2, FFAR1, FFAR4 GAA 1211/4885MAPT 2648/4885TP53 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.